UBS Group’s GreenLight Biosciences Holdings, PBC Warrant GRNAW Stock Holding History

UBS Group’s Portfolio GRNAW Stock Details GRNAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-187	Closed	-$2	–	10329
2023 Q2	$2	Buy	+187	New	+$6	﹤0.01%	8797
2023 Q1	–	Sell	-13	Closed	-$1	–	11092
2022 Q4	$1	Buy	+13	New	+$2	﹤0.01%	10668
2022 Q3	–	Sell	-1,822	Closed	–	–	11359
2022 Q2	$0	Sell	1,822 -3,007	-62%	-$2.42K	﹤0.01%	11351
2022 Q1	$4K	Sell	4,829 -3,106	-39%	-$2.27K	﹤0.01%	9372
2021 Q4	$10K	Buy	7,935 +700	+10%	+$798	﹤0.01%	8830
2021 Q3	$7K	Sell	7,235 -4,006	-36%	-$4.2K	﹤0.01%	8363
2021 Q2	$12K	Buy	+11,241	New	+$9.93K	﹤0.01%	7917

UBS Group's GRNAW Position: Q3 2023 in Review

UBS Group sold out of GreenLight Biosciences Holdings, PBC Warrant (GRNAW) in Q3 2023, closing a stake of 187 shares — an estimated $2 sold.

UBS Group first reported a position in GRNAW in Q2 2021 and held it in 7 quarters. The position peaked at $12K in Q2 2021. 1 fund tracked by Wall St. Rank holds GRNAW as of Q3 2023.

UBS Group reported no remaining GreenLight Biosciences Holdings, PBC Warrant position as of Q3 2023 after selling out during the quarter.
UBS Group sold 187 GreenLight Biosciences Holdings, PBC Warrant shares in Q3 2023, an estimated $2.
UBS Group first reported a position in GreenLight Biosciences Holdings, PBC Warrant in Q2 2021 and held it in 7 quarters.
UBS Group's GreenLight Biosciences Holdings, PBC Warrant position peaked at $12K in Q2 2021.
1 fund tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Warrant as of Q3 2023.

Based on UBS Group's 13F filing for Q3 2023, filed 9 Nov 2023.